At ESMO2025, Mindpeak and AstraZeneca delivered new evidence on how AI can advance precision oncology – sharing results from a multinational study validating AI-assisted HER2 immunohistochemistry (IHC) scoring across 12 academic centres and more than 1,000 breast cancer cases.
“Augmenting HER2 IHC Assessment, Including HER2 Ultralow Scoring, in Breast Cancer with AI Support” demonstrated that AI assistance can meaningfully enhance diagnostic precision and consistency:
- +24% more cases correctly identified as HER2 ultralow
- Interobserver concordance improved from 64% → 80%·
- Diagnostic accuracy elevated to 73.8%·
- 36% shorter reading time per case
These findings show how AI can help pathologists distinguish HER2 low and ultralow expression with greater confidence – a crucial step as new targeted therapies continue to expand treatment options.
Mindpeak remains committed to partnering with leaders across pharma and diagnostics to bring AI-powered precision into everyday pathology practice worldwide.
